- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Examining Data from MonumenTAL-2 Study
The MonumenTAL-2 study is discussed by Rafael Fonesca, MD.
EP: 1.Unmet Needs and Treatment Approaches in Newly Diagnosed Multiple Myeloma
EP: 2.ASH 2023: PERSEUS Trial Overview
EP: 3.Considerations for Combination Therapy and MRD Testing in Newly Diagnosed Multiple Myeloma Patients
EP: 4.ASH 2023: Analyzing IsKia Trial
EP: 5.Examining Data from MonumenTAL-2 Study
EP: 6.Optimizing Bispecific Use in Multiple Myeloma Treatment
EP: 7.Navigating Impact of RRMM Treatment on Patient Quality of Life
EP: 8.Key RRMM-Related Takeaways from ASH 2023
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
The phase 1/2 MonumenTAL-2 study evaluated the combination of the anti-GPRC5D antibody talquetamab and the immunomodulatory drug pomalidomide in relapsed/refractory multiple myeloma. Patients had received a median of 3 prior lines of treatment. Pomalidomide was started at the lower dose of 2 mg (range, 2-4 mg) to manage myelosuppression risks. Stepwise talquetamab dose increases also occurred. Despite some dose reductions, adverse reactions were consistent with each agent’s known single-agent toxicities.
The overall response rate was 94% with talquetamab 0.4 mg/kg weekly, on par with other antibody combinations like talquetamab plus teclistamab. Deep responses occurred, with 44% stringent complete response rate and 63% complete response rate in heavily pretreated patients. Although next steps for talquetamab are still unknown, this data supports continued development of GPRC5D-targeting combinations in myeloma.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Margin Status Likely Not a Factor in STS Recurrence
May 10th 2024The optimal negative margin required following surgical resection and perioperative radiotherapy for extremity soft tissue sarcoma (STS) remains up for debate, with investigators of a new study using Union for International Cancer Control classification to define resection margin.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
